36

AbbVie Inc. (ABBV-N)

ON STOCKCHASE SINCE Jan 2013

0

AbbVie Inc.
ABBV-N

45 watching

Join the Discussion

Expert Opinions
0 comments
Your Reaction

0 0 0 0 0

What the experts are saying about ABBV-N

Signal	Opinion	Expert
BUY	AbbVie Inc.(ABBV-N) November 7, 2018 Just reported earnings last week, beating the street by 6%. It's been sideways, but pays a 4.9% dividend that should grow. Trades at 10x forward earnings at a 11% growth rate. But the market isn't recognizing this now. It's a good healthcare name, and healthcare has been outperforming the S&P in the current late cycle. ABBV has beaten earnings many quarters in a row. 0 0 0 0 0 0 comments	Just reported earnings last week, beating the street by 6%. It's been sideways, but pays a 4.9% dividend that should grow. Trades at 10x forward earnings at a 11% growth rate. But the market isn't recognizing this now. It's a good healthcare name, and healthcare has been outperforming the S&P in the current late cycle. ABBV has beaten earnings many quarters in a row. 0 0 0 0 0 0 0 comments Stan Wong Director &, Private Wealth Manag... Price $86.960 Owned Yes

HOLD	AbbVie Inc.(ABBV-N) September 12, 2018 Likes it, even though flat this year. Pays a nice dividend of 4.1%, which is expected to grow. Likes the healthcare space. Hold on to it and collect the dividend. 0 0 0 0 0 0 comments	Likes it, even though flat this year. Pays a nice dividend of 4.1%, which is expected to grow. Likes the healthcare space. Hold on to it and collect the dividend. 0 0 0 0 0 0 0 comments Stan Wong Director &, Private Wealth Manag... Price $93.240 Owned Yes
WATCH	AbbVie Inc.(ABBV-N) August 21, 2018 This is a fine company. Its primary product is Humira, the most successful drug in the history of the pharmaceutical industry. It represents about 60% of AbbVie’s earnings, which means that AbbVie’s portfolio is not well diversified. This is not unusual for pharma companies. The drug will not go off patent for a few years, but the clock is ticking. The question to ask is whether the company has good replacements in the works. 0 0 0 0 0 0 comments	This is a fine company. Its primary product is Humira, the most successful drug in the history of the pharmaceutical industry. It represents about 60% of AbbVie’s earnings, which means that AbbVie’s portfolio is not well diversified. This is not unusual for pharma companies. The drug will not go off patent for a few years, but the clock is ticking. The question to ask is whether the company has good replacements in the works. 0 0 0 0 0 0 0 comments Gordon Reid President, GoodReid Investment ... Price $97.740 Owned Unknown
BUY	AbbVie Inc.(ABBV-N) July 5, 2018 Is the yield sustainable? They are one of the largest biotech companies out there. They have one primary drug called Humera. It is an $18 billion dollar drug. They made a number of acquisitions. He sees the dividend as sustainable. Good valuation. 0 0 0 0 0 0 comments	Is the yield sustainable? They are one of the largest biotech companies out there. They have one primary drug called Humera. It is an $18 billion dollar drug. They made a number of acquisitions. He sees the dividend as sustainable. Good valuation. 0 0 0 0 0 0 0 comments Paul Macdonald Chief Inve, Harvest Portfolios G... Price $94.480 Owned Yes
BUY	AbbVie Inc.(ABBV-N) June 22, 2018 Nice little pharmaceutical name. 23% EPS growth. Trading at a reasonable 12 multiple. At these levels is OK to accumulate. 0 0 0 0 0 0 comments	Nice little pharmaceutical name. 23% EPS growth. Trading at a reasonable 12 multiple. At these levels is OK to accumulate. 0 0 0 0 0 0 0 comments Greg Newman Director &, Scotia Wealth Manage... Price $95.550 Owned No
DON'T BUY	AbbVie Inc.(ABBV-N) April 24, 2018 A bad acquisition two years ago hit them badly after that new company suffered a negative drug trial. Then, the stock dropped and he sold. There's probably still value in this stock, but he'd rather buy something else. 0 0 0 0 0 0 comments	A bad acquisition two years ago hit them badly after that new company suffered a negative drug trial. Then, the stock dropped and he sold. There's probably still value in this stock, but he'd rather buy something else. 0 0 0 0 0 0 0 comments James Telfser Partner & , Aventine Management ... Price $91.360 Owned No
TOP PICK	AbbVie Inc.(ABBV-N) April 12, 2018 A spin-off from Abbott Laboratories (ABT-N). Strong exposure to immunology and oncology medicines. Dividend Yield of 4.2%. The stock sold off because they had a setback on a cancer drugs, but it is overdone in his opinion. Great way to own a strong growing pharma company. (Analysts’ price target is $120.27) 0 0 0 0 0 0 comments	A spin-off from Abbott Laboratories (ABT-N). Strong exposure to immunology and oncology medicines. Dividend Yield of 4.2%. The stock sold off because they had a setback on a cancer drugs, but it is overdone in his opinion. Great way to own a strong growing pharma company. (Analysts’ price target is $120.27) 0 0 0 0 0 0 0 comments Stan Wong Director &, Private Wealth Manag... Price $92.120 Owned Yes
TOP PICK	AbbVie Inc.(ABBV-N) March 23, 2018 He holds this in a pure technical system portfolio. It was down 13% yesterday and they decided to step in. A lung cancer drug recently announced disappointing results. They see health care in a secular bull market. A hot pick today. 0 0 0 0 0 0 comments	He holds this in a pure technical system portfolio. It was down 13% yesterday and they decided to step in. A lung cancer drug recently announced disappointing results. They see health care in a secular bull market. A hot pick today. 0 0 0 0 0 0 0 comments Hap (Robert) Sn Chief Port, Castlemoore Inc.... Price $97.460 Owned Yes
STRONG BUY	AbbVie Inc.(ABBV-N) March 21, 2018 Really likes this. They put up a monster quarter earlier this year as well as surprise drug trials for dermatitis that came in strong. They've won some patents. It's a $20-billion cash cow that they're reinvesting, some in partnerships with companies like J&J. Everything is working for it. 0 0 0 0 0 0 comments	Really likes this. They put up a monster quarter earlier this year as well as surprise drug trials for dermatitis that came in strong. They've won some patents. It's a $20-billion cash cow that they're reinvesting, some in partnerships with companies like J&J. Everything is working for it. 0 0 0 0 0 0 0 comments Paul Macdonald Chief Inve, Harvest Portfolios G... Price $112.450 Owned Yes
COMMENT	AbbVie Inc.(ABBV-N) September 19, 2017 (Market Call Minute.) A company that was spun off from Abbott Labs (ABT-N) 2 or 3 years ago. A great company, but 66% of their revenue comes from 1 drug, Humira, the best selling drug in the world. 0 0 0 0 0 0 comments	(Market Call Minute.) A company that was spun off from Abbott Labs (ABT-N) 2 or 3 years ago. A great company, but 66% of their revenue comes from 1 drug, Humira, the best selling drug in the world. 0 0 0 0 0 0 0 comments Gordon Reid President, GoodReid Investment ... Price $86.370 Owned Unknown
BUY	AbbVie Inc.(ABBV-N) September 14, 2017 You absolutely have to hold on to it if you have a 2 year outlook. Humera is the largest selling drug in the world. They are forever in patent disputes. They have taken this cash cow and used the proceeds to reinvest in their pipeline. They have a great balance sheet and a great yield. We are seeing great results from their trials. It should have double digit growth and should be at 15 times. It should consolidate higher than where it is. 0 0 0 0 0 0 comments	You absolutely have to hold on to it if you have a 2 year outlook. Humera is the largest selling drug in the world. They are forever in patent disputes. They have taken this cash cow and used the proceeds to reinvest in their pipeline. They have a great balance sheet and a great yield. We are seeing great results from their trials. It should have double digit growth and should be at 15 times. It should consolidate higher than where it is. 0 0 0 0 0 0 0 comments Paul Macdonald Chief Inve, Harvest Portfolios G... Price $89.220 Owned Unknown
PAST TOP PICK	AbbVie Inc.(ABBV-N) August 24, 2017 (Top Pick Jun 23/16, Up 23.30%) He still likes it and it is one of his favourite healthcare names. It has a 12 times PE and 8% long time growth rate. It trades at a discount to its peer group. Humeria is 60% of their revenues so we have to watch this concentration risk. 0 0 0 0 0 0 comments	(Top Pick Jun 23/16, Up 23.30%) He still likes it and it is one of his favourite healthcare names. It has a 12 times PE and 8% long time growth rate. It trades at a discount to its peer group. Humeria is 60% of their revenues so we have to watch this concentration risk. 0 0 0 0 0 0 0 comments Stan Wong Director &, Private Wealth Manag... Price $72.110 Owned Unknown
DON'T BUY	AbbVie Inc.(ABBV-N) June 21, 2017 (Market Call Minute.) The spinoff from Abbott Labs (ABT-N). What makes him hesitate about this is that it is more of a 1 product company with their Humira drug. It represents about 65% of their total revenue, so that presents risks. 0 0 0 0 0 0 comments	(Market Call Minute.) The spinoff from Abbott Labs (ABT-N). What makes him hesitate about this is that it is more of a 1 product company with their Humira drug. It represents about 65% of their total revenue, so that presents risks. 0 0 0 0 0 0 0 comments Gordon Reid President, GoodReid Investment ... Price $71.340 Owned Unknown
COMMENT	AbbVie Inc.(ABBV-N) May 10, 2017 This is kind of the by-product of one of these ultra blockbuster drugs. Their anti-inflammatory franchise is the largest selling drug right now. The company has done a good job of building out their pipeline. They have a cancer drug that is expected to be one of the top 10 by 2020. May 17 is a key date for the company as there is a challenge. Trading at 12X earnings, and going down to 10X with the dividend yield under 4%, so he would be cautious until May 17. 0 0 0 0 0 0 comments	This is kind of the by-product of one of these ultra blockbuster drugs. Their anti-inflammatory franchise is the largest selling drug right now. The company has done a good job of building out their pipeline. They have a cancer drug that is expected to be one of the top 10 by 2020. May 17 is a key date for the company as there is a challenge. Trading at 12X earnings, and going down to 10X with the dividend yield under 4%, so he would be cautious until May 17. 0 0 0 0 0 0 0 comments Paul Macdonald Chief Inve, Harvest Portfolios G... Price $65.980 Owned Yes
PAST TOP PICK	AbbVie Inc.(ABBV-N) April 20, 2017 (A Top Pick Dec 23/16. Up 4%.) A one trick pony with their drug Humira. Valuation is quite reasonable and is going to be 12-13X projected earnings. A lot of that is based on sales of Humira, a life altering drug, which accounts for over 60% of their revenues. Made 2 very large acquisitions in the past few years, and we are starting to see some of those drugs in the pipeline getting approved. 0 0 0 0 0 0 comments	(A Top Pick Dec 23/16. Up 4%.) A one trick pony with their drug Humira. Valuation is quite reasonable and is going to be 12-13X projected earnings. A lot of that is based on sales of Humira, a life altering drug, which accounts for over 60% of their revenues. Made 2 very large acquisitions in the past few years, and we are starting to see some of those drugs in the pipeline getting approved. 0 0 0 0 0 0 0 comments Lorne Zeiler Portfolio , TriDelta Financial... Price $63.780 Owned Yes

Stockchase, in its reporting on what has been discussed by indviduals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : hello@stockchase.com.

© Stockchase Inc. & Wealthica Financial Technology Inc.